Across TCGA pan-cancer cohorts, ZFAND2A-DT RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of ZFAND2A-DT’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ZFAND2A-DT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZFAND2A-DT is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.
LIHC, LUAD, and KIRC are the cancer types where ZFAND2A-DT tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZFAND2A-DT RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.